The Community Pharmacy As a Study Center for the Epidemiological Analysis of the Population Vaccination Against SARS-CoV-2: Evaluation of Vaccine Safety and Pharmaceutical Service

Overview

Journal Pharmacy (Basel)

Date 2024 Feb 23

PMID 38392923

Authors

Jacopo Raffaele Dibenedetto

Michela Cetrone

Marina Antonacci

Domenico Pio Cannone

Stefania Antonacci

Pasquale Bratta

Francesco Leonetti

Domenico Tricarico

Affiliations

Soon will be listed here.

Abstract

We conducted a monocentric observational study aimed at evaluating the vaccine safety and the pharmaceutical service provided at a community pharmacy (C.PHARM) in the Puglia Region in the period from 29 December 2021 to 12 March 2022 using data from 550 patients of various ages and sexes and with concomitant diseases. We collected anamnestic data, the number of hospitalizations, and any post-vaccination adverse reactions. Interviews using the integrated EQ5 method were also performed to evaluate the quality of the service offered and any therapy preference. As expected, the vaccines were reactogenic after the first dose in the patients with mild-moderate reactions, with younger age and female gender as risk factors. Immune-allergic reactions of a moderate-severe degree were observed in adult females. In the elderly, the vaccination was well tolerated. Comirnaty showed a favorable O.R. < 1 vs. other vaccines. No cardiovascular events or hospitalizations were observed up to May 2023. Regional data indicate that all treatments during May 2023 were correlated with the viremia. Paxlovid was prescribed in 3% of the patients in our center and in 1.46% in the region, and distributed/dispensed on behalf of third parties in accordance with a novel distribution/dispensation protocol of the C.PHARM that resulted in a safe vaccination center providing appropriate patient inclusion during vaccination.

References

Lang K . How do we best use Paxlovid and other covid antivirals?. BMJ. 2023; 382:1666. DOI: 10.1136/bmj.p1666. View

Corrao G, Franchi M, Cereda D, Bortolan F, Zoli A, Leoni O . Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy. Lancet Infect Dis. 2022; 22(5):649-656. PMC: 8797009. DOI: 10.1016/S1473-3099(21)00813-6. View

Kalinke U, Barouch D, Rizzi R, Lagkadinou E, Tureci O, Pather S . Clinical development and approval of COVID-19 vaccines. Expert Rev Vaccines. 2022; 21(5):609-619. PMC: 8935460. DOI: 10.1080/14760584.2022.2042257. View

Finney Rutten L, Zhu X, Leppin A, Ridgeway J, Swift M, Griffin J . Evidence-Based Strategies for Clinical Organizations to Address COVID-19 Vaccine Hesitancy. Mayo Clin Proc. 2021; 96(3):699-707. PMC: 7772995. DOI: 10.1016/j.mayocp.2020.12.024. View

Lincoln A, Dixon-Ibarra A, Hanley J, Smith A, Martin K, Bazzano A . Global report on COVID-19 vaccination and reasons not to vaccinate among adults with intellectual disabilities: Results from secondary analyses of Special Olympics' program planning. PLOS Glob Public Health. 2023; 3(6):e0001367. PMC: 10263337. DOI: 10.1371/journal.pgph.0001367. View

Vieyra-Valdez E, Linares-Culebro R, Rosas-Gavilan G, Ramirez-Hernandez D, Dominguez-Casala R, Morales-Ledesma L . Roles of the cholinergic system and vagal innervation in the regulation of GnRH secretion and ovulation: Experimental evidence. Brain Res Bull. 2020; 165:129-138. DOI: 10.1016/j.brainresbull.2020.09.009. View

Delgado-Gallegos J, Padilla-Rivas G, Zuniga-Violante E, Aviles-Rodriguez G, Arellanos-Soto D, Gastelum-Arias L . Determinants of COVID-19 Vaccine Hesitancy: A Cross-Sectional Study on a Mexican Population Using an Online Questionnaire (COV-AHQ). Front Public Health. 2021; 9:728690. PMC: 8661090. DOI: 10.3389/fpubh.2021.728690. View

Tricarico D, Lovaglio S, Mele A, Rotondo G, Mancinelli E, Meola G . Acetazolamide prevents vacuolar myopathy in skeletal muscle of K(+) -depleted rats. Br J Pharmacol. 2008; 154(1):183-90. PMC: 2438991. DOI: 10.1038/bjp.2008.42. View

Torabi P, Hamrefors V, Sutton R, Brignole M, Fedorowski A . Definitive aetiology of unexplained syncope after cardiovascular autonomic tests in a tertiary syncope unit. Europace. 2023; 25(9). PMC: 10505743. DOI: 10.1093/europace/euad247. View

10.

Nachtigall I, Bonsignore M, Hohenstein S, Bollmann A, Gunther R, Kodde C . Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers. BMC Infect Dis. 2022; 22(1):291. PMC: 8960217. DOI: 10.1186/s12879-022-07284-8. View

11.

Sankoda A, Nagae Y, Waki K, Sze W, Oba K, Mieno M . Glycemic Control, Renal Progression, and Use of Telemedicine Phone Consultations Among Japanese Patients With Type 2 Diabetes Mellitus During the COVID-19 Pandemic: Retrospective Cohort Study. JMIR Diabetes. 2023; 8:e42607. PMC: 10698649. DOI: 10.2196/42607. View

12.

Roncati L, Roncati M . Emergency use authorization (EUA), conditional marketing authorization (CMA), and the precautionary principle at the time of COVID-19 pandemic. J Public Health Policy. 2021; 42(3):518-521. PMC: 8314028. DOI: 10.1057/s41271-021-00299-6. View

13.

Visacri M, Figueiredo I, Lima T . Role of pharmacist during the COVID-19 pandemic: A scoping review. Res Social Adm Pharm. 2020; 17(1):1799-1806. PMC: 7334137. DOI: 10.1016/j.sapharm.2020.07.003. View

14.

Copaescu A, Rosa Duque J, Phillips E . What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later. Ann Allergy Asthma Immunol. 2022; 129(1):40-51. PMC: 8979618. DOI: 10.1016/j.anai.2022.03.030. View

15.

Gates D, Cohen S, Orr K, Caffrey A . Demographic and Clinical Predictors of Pharmacist-Administered Pediatric Influenza Immunization. J Pharm Pract. 2023; 37(3):612-624. DOI: 10.1177/08971900231155223. View

16.

Bellos I, Karageorgiou V, Viskin D . Myocarditis following mRNA Covid-19 vaccination: A pooled analysis. Vaccine. 2022; 40(12):1768-1774. PMC: 8818354. DOI: 10.1016/j.vaccine.2022.02.017. View

17.

Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi S, Razvi S . Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021; 27(12):2144-2153. PMC: 8629105. DOI: 10.1038/s41591-021-01556-7. View

18.

Mazzuoli S, Tricarico D, Demma F, Furneri G, Guglielmi F . Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients. PLoS One. 2016; 11(11):e0166443. PMC: 5112916. DOI: 10.1371/journal.pone.0166443. View

19.

Sax J . COVID-19 Vaccine Hesitancy and (Mis)perception of Risk. Am J Law Med. 2022; 48(1):54-90. DOI: 10.1017/amj.2022.13. View

20.

Dooms M . Pharmacists are initiators in palliative care for patients with rare diseases. Orphanet J Rare Dis. 2023; 18(1):141. PMC: 10249311. DOI: 10.1186/s13023-023-02765-8. View